Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a pipeline that spans dermatology creams to oncology biologics means Fortress Biotech’s SEC paperwork quickly balloons past 300 pages. If you have ever wondered how to decode Fortress Biotech insider trading Form 4 transactions or locate the next trial-readout date hidden in an 8-K, you know the challenge. Stock Titan solves it by pairing real-time EDGAR feeds with AI that translates clinical jargon into plain English.
Search once and you’ll see every filing type, from the Fortress Biotech quarterly earnings report 10-Q filing to a sudden 8-K announcing Phase III results. Our AI-powered summaries spotlight what matters—R&D expense swings, subsidiary royalty streams, and upcoming FDA milestones—so you can focus on decisions, not document hunting. Need trading signals? We flag Fortress Biotech Form 4 insider transactions real-time, complete with trend graphics that reveal management conviction long before headline writers notice.
Whether you are comparing cash burn across quarters or checking a Fortress Biotech proxy statement executive compensation, every disclosure is linked, searchable, and annotated. Typical investor tasks become simple:
- Review a Fortress Biotech annual report 10-K simplified to understand pipeline prioritization.
- Dive into Fortress Biotech earnings report filing analysis for segment revenue shifts.
- Get alerts when an Fortress Biotech 8-K material events explained filing details trial results.
- Monitor Fortress Biotech executive stock transactions Form 4 before catalyst dates.
- Explore “understanding Fortress Biotech SEC documents with AI” guides for deeper learning.
With comprehensive coverage, AI-generated plain-language explanations, and instant notifications, Stock Titan turns complex science and legal text into actionable insight—so you never miss the next breakthrough hidden in a footnote.
David Jin, Chief Financial Officer of Fortress Biotech, Inc. (FBIO), reported an acquisition of 2,711 common shares on 10/01/2025 under the company's Employee Stock Purchase Plan at a price of $1.309 per share. The filing states the purchase was exempt under Rule 16b-3(c) and 16b-3(d). After the transaction, Mr. Jin beneficially owns 1,248,604 shares, which the filer says include 1,230,000 shares underlying deferred restricted stock units. The Form 4 is signed and dated 10/02/2025.
Fortress Biotech, Inc. (reporting person) reported a Section 16 filing related to Mustang Bio, Inc. (MBIO). On 09/29/2025 the reporting person received 59,334 shares of Mustang Bio common stock at a reported price of $0, increasing its beneficial ownership to 258,192 shares. The filing states these shares were granted under an agreement that awards the reporting person equity equal to 2.5% of the gross proceeds of any debt or equity financing; the grant followed the issuer’s receipt of proceeds from the exercise of previously issued warrants. The Form 4 is signed by an attorney-in-fact for the reporting person on 10/01/2025.
FAQ
What is the current stock price of Fortress Biotech (FBIO)?
What is the market cap of Fortress Biotech (FBIO)?
